HCPLive

Most Patients with C. difficile Infection Receive Unnecessary Antimicrobials

 
MONDAY, Jan. 21 (HealthDay News) -- The majority of patients with current or recent Clostridium difficile infection (CDI) receive unnecessary antimicrobials, with 26 percent receiving only unnecessary antimicrobials, according to research published in the February issue of Infection Control and Hospital Epidemiology.

In an effort to examine unnecessary antimicrobial use, Megan K. Shaughnessy, M.D., of the Minneapolis Veterans Affairs Health Care System, and colleagues performed a retrospective review of pharmacy and medical records for 246 patients diagnosed with new-onset CDI.

The researchers found that, during and/or after CDI treatment, 57 percent of patients with new-onset CDI received non-CDI antibiotics. More than three-quarters (77 percent) of all patients received at least one dose of unnecessary antimicrobials, and 26 percent received only unnecessary antimicrobials. Unnecessary antimicrobials were included in 45 percent of the total non-CDI antimicrobial days. The most commonly cited reasons for antimicrobial use included suspected pneumonia or urinary tract infection. Fluoroquinolones and β-lactam antibiotics were most often used.

"Non-CDI antimicrobials are often used unnecessarily in patients with a current or recent history of CDI," the authors write. "This suggests that, during this window of heightened risk of CDI recurrence, a large portion of non-CDI antimicrobial use could be avoided, thereby presumably mitigating some of the associated recurrence risk."

One author disclosed financial ties to the pharmaceutical industry.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Phone call reminders to parents about their child’s asthma medications improved adherence levels relative to typical care, according to a study published in JAMA Pediatrics.
Cardiac biomarker testing is often used in emergency department visits even when there is no suspected symptom of acute coronary syndrome, according to research from UT Southwestern Medical Center.
Physicians must decide on a case by case basis which patients will benefit the most from hepatitis C virus therapy, according to an editorial in JAMA Internal Medicine.
Two days after the US Food and Drug Administration announced that testosterone replacement products must now carry warning labels on the risks of heart attack and stroke, 2 researchers presented abstracts of studies indicating that there is no such danger. The studies were publicized by the American College of Cardiology and will be presented in detail at the group's upcoming meeting in San Diego, CA.
$vAR$